Search

Focuses on the inhibition of retinal neovascularization by gene transfer of soluble vascular endothelial growth factor sFlt-1. Treatment of retinal angiogenesis, one of the leading causes of blindness; Induction of proliferative retinopathy in mice; Adenovirus-mediated growth factor protein expression.

Inherited retinal degenerations are a major cause of blindness for which there are currently no effective therapies. Significant progress concerning in vivo gene transfer has allowed retardation of degeneration or retinal functional improvement in different animal models. To date, there has been no evaluation of the impact of these treatments on higher visual function, a critical step for validating gene therapy treatment strategies.Here, we have used adeno-associated (AAV2)-mediated gene transfer of Prph2 in the Prph2Rd2/Rd2 mouse model. We then assessed higher visual function by recording from central visually responsive neurons in the superior colliculus and improvements were correlated in individual animals with retinal function (ERG) and histological and biochemical changes. Although gene replacement therapy only partially restores photoreceptor morphology, it results in a 300% increase of the visual cycle protein rhodopsin, leading to retinal function improvement (250% increase of b-wave amplitude) and significantly higher central visual responses (166% increase at 24 cd/m2). These findings suggest that gene replacement therapy leading to even relatively modest structural improvement may result in improved central visual function. [Copyright &y& Elsevier]